Central Pharmaceutical Joint Stock Company No3 (DP3) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached 95.2 billion VND, up 4.5% year-over-year, with net profit after tax at 21.3 billion VND, a 13% increase from Q3 2023.

• Nine-month cumulative revenue was 301.3 billion VND, down 3.3% year-over-year, while net profit after tax totaled 71.1 billion VND, a 4.9% decrease.

• Gross margin improved to 35.2% in Q3 2024 from 29.2% in Q3 2023, driven by lower cost of goods sold.

Financial highlights

• Q3 2024 gross profit was 34.1 billion VND, up 28.6% year-over-year; operating profit reached 27.0 billion VND, up 14.9%.

• Financial income for the nine months was 8.5 billion VND, down from 13.0 billion VND year-over-year.

• Selling expenses for the nine months were 95.7 billion VND, nearly flat year-over-year; administrative expenses dropped sharply to 23.1 billion VND from 38.6 billion VND.

• Basic EPS for Q3 2024 was 991 VND, up from 878 VND in Q3 2023; nine-month EPS was 3,306 VND.

Outlook and guidance

• Management continues to focus on cost control and efficiency to offset revenue pressure.

• No explicit forward guidance provided, but stable capital structure and cash position support ongoing operations.